We are leaders in

Combination
Immuno-oncology

ImmVirX is a clinical stage oncology company developing novel oncolytic viruses to create powerful cancer immunotherapy combinations.

What we are up to

ImmVirX is actively progressing its novel immuno-oncology agents in the clinic, targeting some of the most prevalent cancer types where patients have limited treatment options.

Our novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce systemic anti-tumour immune responses.

The proprietary bio-selected RNA viruses target specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumour cells while creating beneficial changes in the tumour micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.

In this way, our viral candidates are intended to increase the effectiveness of current immunotherapies, primarily immune checkpoint inhibitors and CAR-T cell therapies, in fighting cancers of high unmet need including colorectal, gastric, hepatocellular and ovarian cancer.

In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories

On Twitter

We have entered into a clinical trial collaboration with leading Chinese pharma group Innovent Biologics to investigate the combination of IVX037 and their checkpoint inhibitor sintilimab in difficult to treat cancers: https://buff.ly/42Vaupt

We’ve received $3.77m R&D as part of the Australian Government’s R&D Tax Incentive programme: https://buff.ly/3uvWYMe

The refund will contribute to the development of our investigational products IVX037 & IVX055 as well as other discovery programmes. #biotech #oncolytics

ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at The @Bell_Potter Healthcare Conference 2023 is now available.

Click here to view the presentation:

Load More